Stay updated on Nivolumab With Azacitidine in AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab With Azacitidine in AML Clinical Trial page.

Latest updates to the Nivolumab With Azacitidine in AML Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing the older site-wide funding/status notice. No study content, eligibility criteria, or outcome measures were altered.SummaryDifference0.3%

- Check21 days agoChange DetectedNotice explains that due to a lapse in government funding, information on this site may not be up to date and that the NIH Clinical Center is open, with updates at cc.nih.gov and opm.gov. The site revision was updated from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedThe page now shows the glossary toggle and updated metadata, adding 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0' while removing 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedLocations section now includes Texas; the old label 'Texas Locations' has been removed. Updated the footer to revision v3.3.3 and removed the 'HHS Vulnerability Disclosure' line.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision: v3.3.2 replaces v3.3.1 on the page. This appears to be an administrative version update with no visible changes to the study details.SummaryDifference0.0%

Stay in the know with updates to Nivolumab With Azacitidine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab With Azacitidine in AML Clinical Trial page.